Current problems in cancer · 2026
Title: Impact of CYP3A5*3 genetic polymorphism on breast cancer risk: Evidence from Bangladesh.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bellah Sm Faysal, Billah S M Saker
Аннотация
BACKGROUND: The CYP3A5 gene plays a crucial role in drug metabolism and carcinogen activation, potentially influencing breast cancer susceptibility. However, its genetic association with breast cancer risk in the Bangladeshi population remains under explored.
OBJECTIVE: This study aims to examine the expression and genetic correlation of the CYP3A5*3 (rs776746) polymorphism in relation to breast cancer susceptibility.
METHODS: A case-control study was performed with 150 breast cancer patients and 150 healthy controls to investigate genotypic variations of the CYP3A5*3 (rs776746) polymorphism using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. The relationship between the CYP3A5*3 variant and breast cancer risk was assessed by calculating odds ratios (ORs) and 95% confidence intervals (CIs) through logistic regression models.
RESULTS: The CYP3A5*3 polymorphism exhibited a significant association with increased breast cancer risks. Breast cancer risk was found to be higher in heterozygotes than in homozygotes. Individuals carrying the heterozygous (*1/*3) and mutant homozygote (*3/*3) genotypes had a 3.04-fold (p = 0.0005) and 1.9-fold (p = 0.0227) increased risk of developing breast cancer respectively. Furthermore, the combined (*1/*3 + *3/*3) genotype was significantly linked to a 3.67-fold higher susceptibility to breast cancer risks (p < 0.0005).
CONCLUSION: Our findings suggest that the CYP3A5*3 polymorphism is significantly associated with an elevated risk of breast cancer in Bangladeshi population.
OBJECTIVE: This study aims to examine the expression and genetic correlation of the CYP3A5*3 (rs776746) polymorphism in relation to breast cancer susceptibility.
METHODS: A case-control study was performed with 150 breast cancer patients and 150 healthy controls to investigate genotypic variations of the CYP3A5*3 (rs776746) polymorphism using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. The relationship between the CYP3A5*3 variant and breast cancer risk was assessed by calculating odds ratios (ORs) and 95% confidence intervals (CIs) through logistic regression models.
RESULTS: The CYP3A5*3 polymorphism exhibited a significant association with increased breast cancer risks. Breast cancer risk was found to be higher in heterozygotes than in homozygotes. Individuals carrying the heterozygous (*1/*3) and mutant homozygote (*3/*3) genotypes had a 3.04-fold (p = 0.0005) and 1.9-fold (p = 0.0227) increased risk of developing breast cancer respectively. Furthermore, the combined (*1/*3 + *3/*3) genotype was significantly linked to a 3.67-fold higher susceptibility to breast cancer risks (p < 0.0005).
CONCLUSION: Our findings suggest that the CYP3A5*3 polymorphism is significantly associated with an elevated risk of breast cancer in Bangladeshi population.